Drugs of Abuse Confirmation/Quantitation - Methadone and Metabolite - Meconium
0092313
Ordering Recommendation
• Use for infant drug testing when only methadone exposure is of clinical interest or when quantity of meconium available for testing is very small (eg, <1 g).
• Preferred test is Drugs of Abuse Panel, Meconium - Screen with Reflex to Confirmation/Quantitation (0092516).
Mnemonic
CONFMTD M
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-4 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
- Patient Preparation
- Collect
- All meconium (blackish material) excreted until milk/formula based stool (yellow-green) appears.
- Specimen Preparation
- Transport 0.5 g (equivalent to 1/2 inch cube) for each separate confirmation required. (Min: 0.13 g or 1/4 inch cube)
- Storage/Transport Temperature
- Room temperature.
- Unacceptable Conditions
- Remarks
- Stability
- Ambient: 1 week; Refrigerated: 3 months; Frozen: 1 year
Reference Interval
Interpretive Data
Drugs Covered: methadone and metabolite (EDDP).
Positive cutoff: 10 ng/g
Meconium begins to form between the 12th and 16th week of gestation. Meconium drug testing can detect maternal drug use during the last 4 to 5 months of pregnancy. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drug use depends on the quantity and quality of the specimen tested as well as the pattern and frequency of drug(s) used by mother. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
For medical purposes only; not valid for forensic use.
Positive cutoff: 10 ng/g
Meconium begins to form between the 12th and 16th week of gestation. Meconium drug testing can detect maternal drug use during the last 4 to 5 months of pregnancy. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drug use depends on the quantity and quality of the specimen tested as well as the pattern and frequency of drug(s) used by mother. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
For medical purposes only; not valid for forensic use.
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Note
Hotline History
N/A
CPT Code(s)
80358 (Alt code: G0480)
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 0092313 | Drug Confirmation, Methadone/Metab, Mec | 29159-1 |
Aliases
- Amidone
- Dolophine
- EDDP
- Heptadon
- Methadone
- Methadose
- Physeptone
- Symoron